Equities analysts expect BioTelemetry Inc (NASDAQ:BEAT) to announce earnings per share (EPS) of $0.39 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioTelemetry’s earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.34. BioTelemetry posted earnings per share of $0.32 in the same quarter last year, which suggests a positive year over year growth rate of 21.9%. The firm is expected to issue its next earnings report on Thursday, February 28th.
According to Zacks, analysts expect that BioTelemetry will report full-year earnings of $1.72 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.82. For the next year, analysts expect that the business will report earnings of $1.72 per share, with EPS estimates ranging from $1.59 to $1.80. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, October 30th. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.21. The business had revenue of $100.00 million for the quarter, compared to analysts’ expectations of $97.89 million. BioTelemetry had a net margin of 4.34% and a return on equity of 22.56%. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.16 EPS.
BEAT traded up $1.31 during midday trading on Friday, hitting $66.73. 33,184 shares of the company traded hands, compared to its average volume of 546,525. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.50 and a current ratio of 2.68. The stock has a market capitalization of $2.14 billion, a P/E ratio of 69.28, a P/E/G ratio of 3.73 and a beta of 1.58. BioTelemetry has a 52 week low of $23.30 and a 52 week high of $66.45.
In other news, Director Robert J. Rubin sold 8,489 shares of the stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $60.36, for a total value of $512,396.04. Following the transaction, the director now owns 140,040 shares in the company, valued at approximately $8,452,814.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kirk E. Gorman sold 625 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $62.30, for a total transaction of $38,937.50. Following the completion of the transaction, the director now owns 173,940 shares in the company, valued at approximately $10,836,462. The disclosure for this sale can be found here. Insiders sold a total of 205,852 shares of company stock worth $12,869,047 in the last quarter. Company insiders own 8.30% of the company’s stock.
Several large investors have recently modified their holdings of BEAT. Thompson Davis & CO. Inc. increased its holdings in BioTelemetry by 112.0% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,650 shares of the medical research company’s stock worth $119,000 after acquiring an additional 1,400 shares in the last quarter. Globeflex Capital L P increased its holdings in BioTelemetry by 19.0% in the 2nd quarter. Globeflex Capital L P now owns 9,400 shares of the medical research company’s stock worth $423,000 after acquiring an additional 1,500 shares in the last quarter. Intrust Bank NA increased its holdings in BioTelemetry by 12.1% in the 2nd quarter. Intrust Bank NA now owns 15,162 shares of the medical research company’s stock worth $682,000 after acquiring an additional 1,639 shares in the last quarter. Legal & General Group Plc increased its holdings in BioTelemetry by 2.9% in the 1st quarter. Legal & General Group Plc now owns 57,741 shares of the medical research company’s stock worth $1,778,000 after acquiring an additional 1,653 shares in the last quarter. Finally, Spectrum Management Group Inc. purchased a new stake in BioTelemetry in the 3rd quarter worth approximately $115,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.